NCT07150338View on ClinicalTrials.gov

Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Progressive Chronic Kidney Disease

CompletedOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

April 20, 2022

Study Completion Date

November 20, 2022

Conditions
Chronic Kidney Disease (Stage 3-4)Chronic Kidney Disease (Stages 4 and 5)Proteinuria
Interventions
DRUG

QRX-3

Compounded new drug regime

DRUG

Eseronate

Neukidney innovative drug

Trial Locations (1)

77504

Premier Kidney clinic, Pasadena

All Listed Sponsors
lead

Neukidney Inc.

INDUSTRY